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Abstract
Background: Portal hypertension and cardiac alterations previously described as “cirrhotic cardiomyopathy” are
known complications of end stage liver disease (ELD). Cardiac failure contributes to morbidity and mortality,
particularly after liver transplantation and transjugular intrahepatic portosystemic shunt (TIPS). We sought to identify
myocardial tissue characterization and evaluate cardiovascular magnetic resonance (CMR) for diagnosis of cardiac
impairment.
Results: Twenty ELD patients underwent CMR for morphological, functional and tissue characterization by late
gadolinium enhancement (LGE). Based on extent of LGE, patients were dichotomized into high and low LGE
groups and analyzed regarding liver, cardiocirculatory and renal functions. CMR demonstrated hyperdynamic left
ventricular function and a patchy pattern of LGE of the myocardium to a variable extent (range 2-62%) in all
patients. There were no significant differences in Model for End-Stage Liver Disease (MELD), Child-Pugh score or
the left ventricular ejection fraction between high and low LGE groups. QTc-interval was prolonged in 25% of the
patients. E/A ratio was at the upper limit of norm; no difference between groups. Patients showing high LGE had a
higher CI (p < 0.05). Biomarkers of myocardial stress were elevated. While NT-proBNP and c-Troponin-T showed no
differences, PLGF and sFLT1 were lower in the high LGE group.
Conclusion: CMR shows myocardial involvement in patients with ELD resembling appearance of myocarditis. The
hyperdynamic circulation in portal hypertension may be an important factor. Larger prospective trials are warranted
to confirm the association with severity and outcome of liver disease and to test the predictive power of CMR for
patients listed for liver transplantation.
Background
End stage liver disease (ELD) regularly leads to major
alterations in the regulation of the cardiovascular sys-
tem. Portal hypertension and/or hormonal changes in
ELD induce a hyperdynamic circulatory state character-
ized by arterial hypotension and tachycardia and are
often accompanied by ascites and electrolyte distur-
bances. Recent data also emphasizes the impact of liver
function on renal (hepatorenal syndrome) and pulmon-
ary (hepatopulmonary and portopulmonary syndrome)
circulation [1], [2]. Driven by the high morbidity and
mortality, significant research has been devoted to the
causes and treatment of renal and pulmonary manifesta-
tions. Contrary to these efforts, little data is available on
myocardial changes due to ELD. Although the hypoth-
esis of ethanol-induced cardiomyopathy has been
around for several decades, the role of the heart in the
hypercirculatory state itself has only been addressed in a
small number of studies [3], [4], [5]. Apparently, the
hypercirculatory state was considered as proof of normal
contractile function of the heart. A decreased ejection
fraction is found only in a minority of cases with ELD.
Some researchers propagateas p e c i f i cd i s e a s ee n t i t y
called “cirrhotic cardiomyopathy” for the cases of
advanced reduction of ejection fraction and for more
subtle evidences of functional impairment such as
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activity/stress, reduced heart rate variability, or altered
E/A in echocardiography eventually resulting in higher
morbidity and mortality pre- and post-OLT[6], [3]. The
improved survival of patients with ELD after orthotopic
liver transplantation (OLT) and the hypercirculatory
state after OLT and transjugular intrahepatic portosyste-
mic shunt (TIPS) have directed research interests
towards the myocardium [7], [8], [9].
Cardiovascular magnetic resonance (CMR) has
become the gold standard method for the assessment of
cardiac morphology and function in various cardiomyo-
pathies (CMP) [10]. Areas of high signal intensity
appearing 10-15 min after injection of the intercellular
contrast agent gadolinium were first described as late
enhancement (LGE) in regions of myocardial scarring
after myocardial infarction [11]. This technique allows
an additional, excellent imaging modality for the analysis
of intercellular matrix. LGE can be detected in post-
infarct scars, inflammation,a sw e l la sn o n - i s c h e m i c
CMP, cardiac neoplasm and storage diseases such as
amyloidosis. Typical LGE patterns have been defined for
each of these diseases [12]. Moreover the extent of LGE
is associated with the amount of affected myocardial tis-
sue, e.g. in myocarditis or ischemic cardiomyopathy
[13]. CMR is the preferred test for the repeated evalua-
tion of disease course due to the lack of radiation and
its non-invasive character [14].
Here we used CMR and serological markers for the
evaluation of functional myocardial changes, non-inva-
sive tissue characterization and the identification of spe-
cific cardiac lesions in cirrhotic patients listed for liver
transplantation.
Methods
Patients
From March 2007 until July 2008, 20 consecutive
patients with ELD had a CMR scan at the department
of cardiology of the University of Heidelberg, Germany.
All patients had been referred by the department of gas-
troenterology of the University of Heidelberg, Germany
for evaluation of cardiac functional analysis. Exclusion
criteria were decreased kidney function (glomerular fil-
tration rate below 30 ml/min/1.73 m
2) and general con-
traindications to CMR (e.g., metal implants, pacemaker,
and claustrophobia). All procedures used in this study
complied with the Declaration of Helsinki, were
approved by our local ethics committee, and all patients
gave written informed consent.
All patients were listed for liver transplantation. Two
were waiting for re-transplantation due to chronic trans-
plantation failure. Clinical characteristics are shown in
Table 1. The mean age was 52.4 ± 9.4 years. The etiol-
ogy of cirrhosis was alcohol in 12 patients, virus
infection in three, autoimmune disease in three, and
cryptogenic in two patients, no patient suffered from
malignant disease. Gender distribution was 11 male and
9 female. The median Child-Pugh score was 9 (range
5-11) and the mean Model for End-Stage Liver Disease
(MELD) score was 14.9 ± 6.3. No patient revealed clini-
cal signs of impaired left ventricular dysfunction except
one who had been diagnosed as “alcoholic cardiomyopa-
thy” and showed moderately impaired left ventricular
function. All patients were on therapy with non-selective
beta-blockers (Propanolol).
Routine echocardiography was performed on a Philips
ie33 echo system (Philips Medical Systems, Nether-
lands). Doppler ratio of early to late transmitral flow
velocity (E/A) was calculated.
Healthy reference group
The hemodynamics of ELD patients were compared
with a healthy reference group of 120 volunteers within
our center. Subjects were considered as healthy (mean
age was 42.0 ± 12.9 years) when no severe diseases were
found in their medical history and a clinical examina-
tion, routine blood paramet e r s ,E C G ,b l o o dp r e s s u r e
measurements, spirometry as well as dobutamine stress
and LGE CMR were within a normal range..
CMR
All images were acquired with a 1.5 T magnetic reso-
nance imaging system (ACHIEVA, Philips Medical Sys-
tems, Netherlands), a flexible cardiac five-element
Table 1 Patient characteristics
Parameter (n = 20) Cirrhosis
patients
Controls
Age (mean ± SD) [years] 52.4 ± 9.4 (24-68) 42.0 ± 12.9 (24-
69)
Body mass index (mean ± SD)
[kg/m
2]
25.6 ± 4.9 (16.9-
34.0)
24.2 ± 3.3 (18.9-
33.0)
Sex (M/F) 11/9 60/60
Bilirubin (mean ± SD) [mg/dL] 4.68 ± 6.7 (0.33-
28.8)
N/A
Albumin (mean ± SD) [g/L] 30.34 ± 7.2 (19-
46)
N/A
MELD score (mean ± SD) 14.9 ± 6.3 (6.4-
28.5)
N/A
Child-Pugh score (median) 9 (5-11) N/A
Etiology
Alcoholic 12
Non-alcoholic 8
Autoimmune 3
Viral 3
Cryptogenic 2
MELD score Model for End-Stage Liver Disease; Range is in brackets, SD
standard deviation, N/A not assessed
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Page 2 of 10phased array coil and a vector electrocardiogram for R
wave triggering using a standard MRI imaging protocol.
In brief, multiple short axis (SAX) cine images using a
steady state free precession sequence with parallel ima-
ging (balanced Fast Field Echo (FFE); Repetition time
(TR)/Echo time (TE) = 2.9/1.45 ms; reconstructed
voxel-size = 1.5 × 1.5 × 8 mm acquisition; sensitivity
encoding (SENSE)-factor = 2) were acquired after the
acquisition of true two- and four- chamber planes for
the assessment of left ventricular ejection fraction
(LVEF %).
A 2D FFE multi-slice SAX inversion recovery
sequence (TR/TE = 2.9/1.0; reconstructed voxel-size =
2.0 × 2.0 × 5 mm acquisition; SENSE-factor = 2; TI =
200 - 280 ms) 10 minutes post-Gd (Gd = 0.2 mmol/kg
of gadopentetate dimeglumine (Schering, Berlin, Ger-
many)) was employed for the measurement of LGE.
The scan protocol was carried out in the following
order: after a survey and reference scan, balanced cine
FFE were acquired in 2-chamber, 4-chamber, short axis
(multi-slice), and 3-chamber orientations. LGE scans
were carried out in SAX, 4-chamber, and 2-chamber
orientations 10 minutes after the injection of gadoli-
nium. The inversion time was chosen very carefully by
performing a T1 mapping using a lock locker sequence
in each patient to estimate the correct inversion time
(Fig. 1). The evidence of LGE was confirmed by imaging
different views of the myocardium (i.e. 4 chamber view,
2 chamber view as well as short axis views).
Image analysis
All CMR images were analyzed on a commercially avail-
able Cardiovascular Magnetic Resonance workstation
with standard software (Philips Viewforum, Version 5.0,
Best, Netherlands) by consensus reading of two blinded
experienced observers.
Definition of global LV function
For cine imaging, a modified 16-segment model accord-
ing to the AHA definition [15] for the left ventricle was
used to analyze left ventricular function and delayed
enhancement per segment.
LV global function were calculated by the Philips View
Forum software, version 5.0, after the manual tracing of
the endocardial contours of the left ventricular wall at end
diastole and end systole on the short axis cine data set.
Analysis of late gadolinium enhancement
Segmental enhancement was quantified by the Philips
View Forum Software 5.0 in all 16 segments and
declared as a percentage of LGE of LV mass (Fig. 2).
Signal intensity was measured as mean signal intensity
plus standard deviations of mean (SD) for intra-indivi-
dual analysis. Enhancement was defined as a signal
intensity greater than five SD above the acquired mean
signal intensity level [16].
To evaluate the association of late enhancement with
the indices of cardiovascular stress or with indices of
liver disorders, we dichotomized the patients in two
equally large groups in respect to the percentage of
myocardium with late enhancement.
Clinical scores and blood tests
Blood sampling was carried out on the same day of the
MRI scan. Blood samples were sent to the central
laboratory of the University Hospital Heidelberg for rou-
tine parameters. Plasma aliquots were frozen at -80°C
until biomarker assays were performed. High sensitivity
Troponin T (hsTNT) was measured with a pre-commer-
cial assay by electrochemo-luminescence methods
(Roche Diagnostics, Mannheim, Germany).
Cardiac Troponin T (cTNT) was measured using the
4
th generation commercial one-step electrochemilumi-
nescence assay based on electrochemoluminescence
technology (Elecsys 2010, Roche Diagnostics, Man-
nheim, Germany).
N-terminal prohormone brain natriuretic peptide
(NT-proBNP) was measured using a highly sensitive and
specific electrochemluminescence immunoassay (Elecsys
proBNP, Roche Diagnostics, Mannheim, Germany). The
measurement range extends from 5 to 35,000 pg/mL.
The minimal detectable concentration is 5 pg/mL and
the coefficient of variation is 5.7% at 64 pg/mL.
PLGF and sFLT1 were measured using Elecsys® PLGF
(measurement range extends from 3 to 10,000 pg/mL)
und Elecsys® sFLT1 (measurement range extends from
10 to 85,000 pg/mL) routine assays by Roche Diagnos-
tics, Mannheim, Germany.
Figure 1 T1 Mapping intensity graph based on a lock locker
sequence to quantify the optimal inversion time for LGE
imaging.
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All statistical analyses were performed using SPSS 16
(SPSS Inc. Chicago, Illinois). Parametric (t tests) and
non-parametric (Mann-Whitney U test) tests were used
for continuous data. In addition, the Fisher exact test
was used where applicable. All p < 0.05 were considered
statistically significant.
Results
Evidence of hyperdynamic circulation in ELD patients
Hemodynamic parameters measured by CMR of the
patients are shown in Table 2 and were then compared
to data of the healthy reference group. Values are given
as mean and +/- standard deviation: Heart rate was
74.9 ± 11.9/min (reference group 64.8 ± 9.4/min,
p <0.01) and stroke volume 107 ± 20.8 mL (reference
group 91.7 ± 30.3 mL, p = 0.08). Left ventricular ejection
fraction (LVEF) was 72 ± 7.5% with a range from 49% to
83% (reference group 65.8 ± 6.96% with a range from
32.8% to 84%, p < 0.01). Cardiac output was 7.9 ± 1.63
L/min with a range from 4.4 to 11.1 L/min (reference
group 6.7 ± 1.6 L/min with a range from 3.5 to 12.5,
p < 0.01). The resulting CI yielded 4.36 ± 0.86 L/min/m
2,
ranging from 3.41 to 6.48 L/min/m
2 (reference group
3.6 ± 0.7 L/min/m
2,r a n g i n gf r o m2 . 1t o6 . 3L / m i n / m
2,
p <0.001). Left-ventricular end-diastolic volume was
150.0 ± 35.4 mL (reference group 149.4 ± 33.8 mL,
p = 0.91). These changes were in line with previous
observations of hyperdynamic circulation as part of the
altered cardiovascular regulation in patients with ELD.
LGE CMR
We found variable degrees of LGE in all patients exam-
ined, indicative of myocardial injury despite hypernor-
mal circulatory indices (Fig. 3). The amount of LGE
measured in percentage of myocardium revealed a mean
of 27% ± 16.5% and showed a patchy pattern similar to
patients with myocarditis [17]. The minimum amount
Figure 2 LGE quantification in short-axis orientation in ELD patients with low LGE (detected by orange dots, 11% of myocardial mass
(A) and a normal subject without delayed enhancement (B). LV = left ventricle, RV = right ventricle, S = interventricular septum, * p < 0.05
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median was 25%. The detection of these changes was
independent of the etiology of liver disease and was
observed in patients with alcohol-induced, virus-related,
autoimmune or cholestatic hepatic disease. No LGE was
found in the reference group.
Relationship of LGE with clinical indices of liver disease
We dichotomized the patients regarding the percentage
of myocardium with late enhancement resulting in a
high LGE group and a low LGE group (Fig. 2). We
examined whether the parameters of liver disease were
significantly different between the groups. However,
there was no significant difference between the high and
low LGE groups regarding MELD and Child-Pugh
scores, nor single components of these composite scores
(Table 3).
Since alcohol is regularly considered to impair cardiac
function and alcoholic cardiomyopathy is a known com-
plication of chronic alcohol consumption, we analyzed
the association of the etiology of cirrhosis and the extent
of LGE. In our cohort, a high LGE could be found in a
significantly higher extent in the alcoholic cirrhosis
group than in the non-alcoholic cirrhosis group (Table
4).
Extent of LGE
We analyzed whether the amount of LGE was associated
with functional parameters of the cardiovascular system
in the low and high LGE groups. There were no signifi-
cant differences in stroke volume, ejection fraction,
heart rate, and systolic and diastolic arterial blood pres-
sure between these two groups (data not shown). Since
hyperdynamic circulation to a varying degree was found
in all patients in out study group, we examined the car-
diac output, CI and presence or absence of hyperdy-
namic status defined as a Cardiac Index (CI) of greater
than or equal to 4 L/min/m
2,o rl e s st h a n4L / m i n / m
2,
respectively. Cardiac output showed a trend (p = 0.073)
and CI (p = 0.014, Fig. 4) and hyperdynamic status
(p = 0.029, Table 5) were significantly different between
the low and high LGE groups. To evaluate established
indicators for cirrhotic cardiomyopathy in our cohort
we analyzed QTc-interval and signs of impaired diastolic
function on echocardiography. Though QTc-interval
was prolonged in 25% of the patients, E/A ratio by
echocardiography was normal in all patients.
Serological markers of cardiomyopathy
NT-proBNP and hsTroponin T are established serological
markers of ischemic and non-ischemic CMP and serum
levels of these proteins were measured and these values
were markedly increased in these patients (Table 6), while
cTNT was within normal ranges.
We measured other biomarkers which have been asso-
ciated with cardiomyopathy; of these, PLGF showed a
significant correlation and sFLT1 showed a strong trend.
Both were decreased in the high LGE group (Fig. 5).
Discussion
Liver failure in patients with ELD was the major life lim-
iting factor until OLT has become the therapeutic option
of choice resulting in a major improvement of survival.
Subsequently, other comorbidities have become more
apparent and clinically relevant. The increasing rates of
cardiovascular complications after liver transplantation
have raised the question of the underlying reasons for
heart failure and electrical abnormalities. The increasing
number of patients who receive liver transplantation has
conferred a substantial body of evidence for hemody-
namic deterioration following surgery. Accordingly, rates
of pulmonary oedema have been reported to occur in up
to 56% of liver transplant recipients following surgery,
and hemodynamically significant arrhythmias in 27%,
and congestive heart failure in as many as 5.6% [18]. In a
more recent study, 82/179 patients after OLT suffered
from cardiac decompensation and cardiac causes were
the leading cause of death in these patients [9]. Although
Table 2 Hemodynamic characteristics
Parameter/mean ± SD Cirrhosis patients Controls p
Late enhancement [%] 27 ± 16.5 (2-62) N/A N/A
Cardiac index [L/min/m
2] 4.36 ± 0.86 (3.41-6.48) 3.6 ± 0.74 (2.10-6.31) < 0.01
Ejection fraction [%] 72 ± 7.5 (49-83) 66 ± 7.0 (33-84) < 0.01
Stroke volume [mL] 107 ± 20.8 (81-154) 97.4 ± 20.5 (53-155) 0.08
Cardiac output [L/min] 7.9 ± 1.63 (4.4-11.1) 6.7 ± 1.64 (3.5-12.5) < 0.01
Heart rate at rest [bpm] 74.9 ± 11.9 (50-104) 64.8 ± 9.4 (45-91) < 0.01
Syst. blood pressure rest [mmHg] 109.8 ± 14.4 (92-132) 126.4 ± 11.5 (105-160) < 0.01
Diast. blood pressure rest [mmHg] 61.2 ± 7.8 (44-76) 76.4 ± 9.0 (46-104) < 0.01
LVEDV [mL] 150.9 ± 36.4 (98-221) 149.4 ± 33.8 (87-252) 0.91
LVEDV left ventricular enddiastolic volume; Range is in brackets; Mann-Whitney-U test for differences was performed
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diac disease are independent predictors of death due to
cardiac cause, established risk assessment–including
ECG, echocardiography, coronary angiography, and myo-
cardial perfusion scintigraphy–fails to predict a compli-
cated perioperative course or death attributed to
cardiovascular events. A good diagnostic means for
investigating cardiocirculatory changes before OLT is
still lacking. For this reason, better detection of patients
at risk for cirrhotic cardiomyopathy is required.
We therefore used CMR as the gold standard for the
imaging of cardiomyopathies and biomarkers as well-
established tools for the detection of heart failure. In
line with previous findings, all patients in our study
group showed a hyperdynamic cardiac function [4] (i.e.
increased heart rate and cardiac output at rest suggest-
ing healthy hearts). In contrast, NT-proBNP and hsTNT
were elevated in those patients, indicating a concealed
form of heart failure. One could hypothesize that these
markers are evidence of a barely compensated cardiocir-
culatory system close to the edge of decompensation.
Since hsTNT is supposed to uncover minimal
damages of myocardial tissue [19], we performed LGE
CMR to detect potential myocardial injury. One major
finding in this study is that CMR allows detection of
LGE in patients with end-stage liver disease.
LGE was traditionally only considered to be associated
with fibrosis due to ischemic heart disease [11] but was
then also described in non-ischemic cardiomyopathies,
in infiltrative disorders such as amyloidosis and Fabry’s
disease [12], More recent reports have suggested there
is enhancement in regions of myocarditis [20]. LGE can
therefore be caused by fibrosis or pathological deposits
in the myocardium as well as an inflammatory process.
Recent work could show that the pattern of LGE is
indeed characteristic of different cardiac diseases, allow-
ing for an even better diagnosis and etiological alloca-
tion [21,22].
Though LGE could be detected in patients regardless
of etiology of liver disease, indicating a common
mechanism originating from cirrhosis, the extent of
LGE was more pronounced in patients with alcoholic
liver cirrhosis. This supports the hypothesis of an addi-
tional modifier originating from alcohol abuse. The pat-
chy pattern of LGE in our study group is comparable to
the pattern found in acute myocarditis, where a partial
reversibility of LGE in the chronic phase was described
Figure 3 LGE imaging in a normal subject who showed no signs of late enhancement in a four-chamber view (A). Patient suffering from
ELD. Patchy pattern of delayed contrast enhancement (B and C). LA = left atrium, RA = right atrium, LV = left ventricle, RV = right ventricle, S =
interventricular septum
Table 3 Parameters of liver disease
Parameter Low LGE High
LGE
p (Mann-Whitney
U)
MELD (mean ± SD) 15.7 ±
5.2
12.3 ±
4.7
0.15
Child-Pugh Score (median;
range)
10; (7-11) 8; (5-11) 0.12
Bilirubin (mean ± SD) [mg/
dL]
4.4 ± 5.3 2.1 ± 1.4 0.40
Creatinine (mean ± SD) [mg/
dL]
1.0 ± 0.5 1.1 ± 0.6 0.87
INR (mean ± SD) 1.46 ±
0.38
1.15 ±
0.16
0.06
Age (mean ± SD) [years] 50.9 ±
14.0
53.3 ±
6.0
1.00
MELD score Model for End-Stage Liver Disease, INR International normalized
ratio for Quick value; Range is in brackets, SD standard deviation
Table 4 LGE vs alcoholic etiology
N Non-alcoholic cirrhosis Alcoholic cirrhosis
Low LGE 5 2
High LGE 1 7
P = 0.041 (Fisher Exact Test), LGE late gadolinium enhancement
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show markedly elevated levels of conventional cTNT,
which could not be detected in our cohort. The pattern
differs from other non-ischemic CMP or after myocar-
dial infarction, as mentioned before. Interestingly, there
is a striking mismatch between the degree of LGE and
the degree of LV function. Although a mean of 27% of
the myocardial mass was affected by LGE, only one
patient disclosed depressed systolic LV function. This
indicates that the detected LGE in this study may not be
due to fibrosis, but rather caused by pathological depos-
its (e.g., accumulated cardiotoxic metabolites, oxygen
supply/demand mismatch due to arteriovenous pulmon-
ary shunts, inflammation, a yet unknown mechanism).
This might be explained by the findings of previous stu-
dies, which showed that cardiomyocytes and the trabe-
cular network of the myocardium are changed in
cirrhotic patients [3]. Histological specimens to examine
possible alterations were not available in our patients.
In order to analyze correlations of established clinical
parameters with LGE, we dichotomized our patient
group, one with low amounts of LGE and one with high
amounts of LGE. This resulted in a cut-off value for
high LGE of approx. 25% affected myocardium. These
two groups were then compared in regard to liver and
cardiocirculatory functions. Interestingly, we could not
find a significant difference in markers of liver function
including MELD and Child scores between these two
groups. An obvious link between liver function and LGE
c o u l dt h e r e f o r en o tb er e c o g n i z e d .N e v e r t h e l e s s ,w e
could demonstrate a significant difference regarding the
CI between the low and high LGE groups. Cirrhosis
leads to portal hypertension of varying extents. Compli-
cations of portal hypertension include the development
of portosystemic collaterals ending among others in
varices bearing the risk for variceal bleeding. Further-
more, portal hypertension results in peripheral and
splanchnic vasodilatation and compensatory hyperdy-
namic cardiac function, which can be measured by an
increased CI. As noted above there is a striking mis-
match between LGE and LV function. In this context it
might appear even more surprising that an even higher
cardiac function as measured by cardiac index is asso-
ciated with higher degrees of LE. This is vice versa to
published data on LGE in other patient cohorts [24].
One could speculate that these circumstances result in a
high cardiac workload burden and an incipient cardiac
decompensation. Another explanation might be that
detection of LGE in cirrhosis patients is caused by dif-
ferent mechanisms. And finally one can not exclude that
the inclusion and exclusion criteria into this study might
have influenced these outcomes. This would be in line
with previous studies regarding cardiocirculatory regula-
tion and hypercirculatory status in cirrhotic patients
showing findings that have not yet been well explained
[3]. In our study we could not find an association
between LGE and other cardiac tests to be related to
cirrhotic cardiomyopathy. Prolonged QTc-interval and
reduced E/A ratio did not correlate with LGE. In fact
the former could only be found in 25% of patients and
the latter was normal in all patients. This might be
attributed to the fact, that the aim of this study was not
to examine patients with overt cardiac alterations, but
detect common changes found in not preselected
patients.
Since performing CMR might not be feasible in all
ELD patients or contraindicated, we investigated several
Figure 4 Box plots of CI data are shown. The more pronounced
hyperdynamic circulation in the high LGE group (right) compared
to the low LGE group is depicted (p = 0.029).
Table 5 LGE vs CI
N CI < 4 L/min/m
2 CI ≥ 4 L/min/m
2
Low LGE 6 1
High LGE 1 6
P = 0.029 (Fisher Exact Test), LGE late gadolinium enhancement
Table 6 Established and potential serological markers of
cardiomyopathy
Marker (mean ±
SD)
Low LGE High LGE P (Mann-Whitney
U)
NT-proBNP [ng/L] 125.3 ±
82.2
101.8 ±
64.1
0.18
hs-TNT [ng/L] 5.6 ± 4.2 7.4 ± 3.8 0.56
sFLT1 [ng/L] 143.7 ±
22.6
77.1 ± 21.2 0.06
PLGF [ng/mL] 36.8 ± 10.3 20.6 ± 2.2 0.02
hsTNT high sensitivity cTNT, LGE late gadolinium enhancement, NT-proBNP N-
terminal prohormone brain natiuretic peptide, hsTNT high sensitivity cTNT,
sFLT1 soluble short form of vascular endothelial growth factor receptor-1,
PLGF placental growth factor
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and PLGF were decreased in patients in the high LGE
group. sFLT1 is the soluble short form of vascular
endothelial growth factor receptor-1 (VEGFR-1), a
member of the VEGFR family. It has been shown to
interact with placental growth factor (PLGF). The invol-
vement of both proteins in angiogenesis, the circulatory
and renal dysregulation in preeclamptic patients, and
more recently as part of the development of athero-
sclerosis have all been discussed [25], [26]. Most inter-
estingly, VEGF, its receptors and PLGF have been
implied in the regulation of neovascularization in portal
hypertension. This implication not only points to new
d i a g n o s t i cb u ta l s ot on e wt h erapeutic approaches [27],
[28]. Based on these data, one might speculate that
these factors also play a role in circulatory dysregulation
in ELD patients. Additionally, these biomarkers might
be instrumental in detecting patients at risk and in
monitoring them over time. No differences in other
potential biomarkers were observed between the two
groups.
How might these data affect clinical practice? Cardiac
complications are a frequent cause of morbidity and
mortality in patients undergoing liver transplantation
and TIPS. These two interventions pose a stress on the
cardiocirculatory system and can lead to a decompensa-
tion of cardiac function. This occurs despite regular and
careful previous cardiological evaluation [9]. To our
Figure 5 The differences in serological markers of CMP are shown as box plots.( A) PLGF was significantly decreased in the high LGE
group (p = 0.016). (B) sFLT1 showed a strong trend to be decreased in the high LGE group (p = 0.057) (C) NT-proBNP was not significantly
different between the two groups, but very high values ( > 1000 ng/L) could only be found in the high LGE group, * p < 0.05
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hsTNT elevation in patients with ELD. CMR and
hsTNT as well as NT-proBNP might enable clinicians
to detect myocardial alterations, which is usually ham-
pered by the hyperdynamic LV function in these
patients. Further and larger studies are needed to con-
firm our results and in addition allow for more subtle
subgroup analysis and focus on outcome data. These
could then lead to a new risk stratification for cardiac
complications based on these new diagnostic assess-
ments and subsequently to an adapted and optimized
perioperative management or to a treatment of the myo-
cardial alterations itself. Furthermore it could lead to the
exclusion of patients from OLT or TIPS due to high risk
of development of heart failure after these interventions.
The association of the degree of LGE and hyperdy-
namic status in portal hypertension that could be
demonstrated warrants further investigation and might
be the basis for future studies examining its pathophy-
siological backgrounds.
Since previous studies could demonstrate a normaliza-
tion of the hemodynamic parameters after liver trans-
plantation in ELD patients [29], further studies have to
be done, including follow-up measurements investigat-
ing the extent of a possible reversibility of these myocar-
dial alterations.
Conclusions
Based on our findings, we conclude that myocardial
alterations have a high prevalence among ELD patients,
can be superbly detected and quantified by CMR and
are linked to portal hypertension. Their exact role
related to “cirrhotic cardiomyopathy” has to be deter-
mined. Due to its unique ability to provide non-invasive,
highly sensitive tissue characterization combined with
functional analysis, CMR may become the gold standard
for the diagnosis of myocardial alterations and its sever-
ity as it is in other cardiac diseases. Future experimental
and clinical work including outcome analysis is needed
to clarify the mechanism and possible consequences for
risk stratification and treatment, especially regarding
patients undergoing TIPS or liver transplantation.
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